The development and progression of IgA nephropathy involves multiple pathogenic mechanisms, and therefore the combination of ACTH and a second immunosuppressive agent that simultaneously targets different pathogenic pathways confer superior benefit. The gene discussed is POMC; the disease is IgA glomerulonephritis.